# TRIANGLE MULTI-SERVICES CORPORATION FINANCIAL STATEMENTS SEPTEMBER 30, 2010

SUMMARY	Page
Auditors' Report	3
Balance Sheet	4
Statement of Deficit	5
Statement of Operations	6
Statement of Cash Flow	7
Notes to Financial Statements	8-10



### **AUDITORS' REPORT**

To the Shareholders of Triangle Multi-Services Corporation

We have audited the balance sheet of Triangle Multi-Services Corporation as at September 30, 2010 and the statements of earnings, deficit and cash flows for the year then ended. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audit.

We conducted our audit in accordance with Canadian generally accepted auditing standards. Those standards require that we plan and perform an audit to obtain reasonable assurance whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation.

In our opinion, these financial statements present fairly, in all material respects, the financial position of the Company as at September 30, 2010 and the results of its operations and its cash flows for the year then ended in accordance with Canadian generally accepted accounting principles.

The financial statements for the year ended September 30, 2009 were audited by another firm of chartered accountants who expressed an opinion on those financial statements without reservation in their report dated December 18, 2009.

Soberman LLP

Chartered Accountants
Licensed Public Accountants

Toronto, Canada January 14, 2011

## TRIANGLE MULTI-SERVICES CORPORATION BALANCE SHEET SEPTEMBER 30, 2010

	2010		2009
\$	242 2,565	\$	143 1,987
	2,807		2,130
	-		475,968
\$	2,807	\$	478,098
\$		;	\$ 7,696
	32,133		9,963
	47,159		17,659
	752,063	7	′52,063
(	796,415)	(29	91,624)
	(44,352)	4	60,439
\$		\$ 4	78,098
	\$	\$ 242 2,565 2,807 - \$ 2,807 \$ 15,026 32,133 47,159 752,063 (796,415)	\$ 242 \$ 2,565 2,807  \$ 2,807  \$ 2,807  \$ 15,026 32,133  47,159  752,063 7(796,415) (29

Approved on behalf of	the Board of Directors
Bruce Lewis, Director	

## TRIANGLE MULTI-SERVICES CORPORATION STATEMENT OF DEFICIT FOR THE YEAR ENDED SEPTEMBER 30, 2010

	2010	2009
BALANCE, BEGINNING OF THE YEAR	\$ (291,624)	\$ 40,348
NET LOSS	(504,791)	(331,972)
BALANCE, END OF YEAR	\$ (796,415)	\$ (291,624)

## TRIANGLE MULTI-SERVICES CORPORATION STATEMENT OF OPERATIONS FOR THE YEAR ENDED SEPTEMBER 30, 2010

	2010	2009
OPERATING EXPENSES		
Administrative expenses	\$ 28,823	\$ 34,022
LOSS FROM OPERATIONS	(28,823)	(34,022)
INTEREST REVENUE	-	91,479
CHARGE FOR LOAN IMPAIRMENT (note 4)	(475,968)	(389,429)
NET LOSS AND COMPREHENSIVE LOSS	\$ (504,791)	\$ (331,972)
BASIC AND DILUTED LOSS PER SHARE	\$ (0.03)	\$ (0.02)

## TRIANGLE MULTI-SERVICES CORPORATION STATEMENT OF CASH FLOW FOR THE YEAR ENDED SEPTEMBER 30, 2010

	2010	2009
OPERATING ACTIVITIES		
Net loss	\$ (504,791)	\$ (331,972)
Non-cash items: Interest receivable Charge for loan impairment	- 475,968	(91,479) 389,429
	(28,823)	(34,022)
Change in non-cash working capital items		
Accounts receivable Prepaid expenses Accounts payable Loans payable	(578) - 7,330 22,170	8,013 6,659 -
	99	(19,350)
INVESTING ACTIVITIES	-	 -
FINANCING ACTIVITIES	 -	 -
INCREASE (DECREASE) IN CASH	99	(19,350)
CASH, BEGINNING OF YEAR	143	19,493
CASH, END OF YEAR	\$ 242	\$ 143

### TRIANGLE MULTI-SERVICES CORPORATION NOTES TO FINANCIAL STATEMENTS SEPTEMBER 30, 2010

### 1. STATUTES OF INCORPORATION AND NATURE OF ACTIVITIES

The company is incorporated under the Laws of the Province of Ontario and is in the business of obtaining and developing businesses with high growth potential. The company is listed on the Canadian National Stock Exchange and is traded under the symbol "TMS".

The company's financial statements are prepared on the going concern basis.

The company's ability to continue as a going concern is dependent upon its ability to fund its working capital through financing or operations. Any proposed transactions (including that described in Note 10 Subsequent events) will be subject to approval by the regulatory authorities concerned, and, in the case of a non-arm's length transaction, will also be subject to approval by the shareholders.

### 2. SIGNIFICANT ACCOUNTING POLICIES

The accompanying financial statements have been prepared in accordance with Canadian generally accepted accounting principles ("GAAP"). All amounts are expressed in Canadian dollars.

### Use of estimates

In preparing the company's financial statements, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the period. Actual results may differ from these estimates, which would impact future results of operations and cash flows.

### Revenue recognition

Interest revenue is accounted for when earned.

### Earnings (loss) per share

Basic earnings (loss) per share is calculated using the weighted average number of common shares outstanding during the year. There were no potential shares outstanding during the current or prior year.

### 3. FUTURE ACCOUNTING CHANGES

### International Financial Reporting Standards ("IFRS")

The Accounting Standards Board ("AcSB") has confirmed that the adoption of IFRS will be effective for interim and annual periods beginning on or after January 1, 2011 for Canadian publicly accountable profit-oriented enterprises. IFRS replaces Canada's current GAAP for these enterprises and is optional for all other enterprises. Comparative IFRS information for the previous fiscal year will also have to be reported. The company plans to adopt these new standards effective in the first quarter of fiscal 2011.

### 3. **FUTURE ACCOUNTING CHANGES** (Continued)

The company is currently in the process of evaluating the potential impact of IFRS on its financial statements. This will be an ongoing process as the International Accounting Standards Board and the AcSB issue new standards and recommendations. The company's financial performance and financial position as disclosed in the company's current GAAP financial statements is not expected to be materially different under IFRS.

### 4. PROMISSORY NOTE

	\$ -	\$ 475,968
Promissory note Interest receivable Loan impairment	\$ 750,000 115,397 (865,397)	\$ 750,000 115,397 (389,429)
	2010	2009

The promissory note is due from a company controlled by a director and shareholder of the company. The note earns interest at 12% per annum, maturing in September 2011. In 2010, the lender no longer had reasonable assurance of timely collection of the full amount of principal and interest on the promissory note. The company ceased accruing interest income on October 1, 2009 (2009 – recognized interest income of \$91,479) and recognized an impairment loss of \$475,968 (2009 - \$389,429) at September 30, 2010.

### 5. Loans payable

Loans payable, which are due to a director and a company wholly owned by him, are non-interest bearing and have no fixed terms of repayment. See Note 9 related party transactions.

### 6. CAPITAL STOCK

### Authorized

Unlimited - Class A shares, voting and participating.

Unlimited - Class B shares, voting, redeemable at any time at the option of the corporation for an amount equal to the fair value of the consideration received at issuance.

Unlimited - Class C preferred shares issuable in series with the following to be fixed with each series: number of shares, designation, rights, privileges, restrictions and conditions including dividend rate and calculation method and payment dates, the redemption, purchase and/or conversion prices, terms of redemption, purchase and/or conversion, any sinking fund or other provisions, may be convertible into Class A shares and voting unless otherwise determined.

Issued

issueu	2010		2009
17,470,003 Class A shares	\$ 752,063	\$ 7	752,063

### 7. FINANCIAL INSTRUMENTS

The carrying amounts of the company's financial instruments, consisting of cash, accounts receivable and accounts payable, approximate their fair values due to their short-term nature. The fair value estimates for loan payable cannot be determined with sufficient reliability as no active market exists for such related party instruments.

### 8. DEFERRED LOSSES

At September 30, 2010 the company has tax losses totalling \$316,231, which expire as follows:

2025	\$	52,580
2026		26,061
2027		68,257
2028		77,042
2030		92,291
	\$	316,231
	Φ	310,231

The future income tax asset resulting from these losses amounts to \$85,400 (2009 - \$60,500). Since it is not more likely than not that the company will be able to realize the benefit of these tax losses at September 30, 2010 and 2009, a full valuation allowance has been provided.

### 9. RELATED PARTY TRANSACTIONS

During the year, the company engaged in transactions with related parties in the normal course of operations. These transactions, which are disclosed in Notes 4 and 5, are measured at the exchange amount which is the amount of consideration established and agreed to by the related parties.

### 10. CAPITAL DISCLOSURE

The company's capital consists of cash and shareholders' equity. The company manages its capital to effectively fund its business and provide a return to shareholders. The company is not subject to any externally imposed capital requirements.

### 11. SEGMENTED INFORMATION

The company operates in one segment and only in Canada.

### 12. SUBSEQUENT EVENTS

On November 26, 2010, the company entered into an exclusive license agreement with Rx 110 Inc. to manufacture, import, market and sell in Canada filler products for stopping mould at source (the "Rx Products").

Pursuant to the terms of the License Agreement, and as compensation for Rx Inc. entering into the License Agreement, the company issued to Rx Inc. 10,000,000 Class A shares in the capital of the company and granted an ongoing royalty equal to 3% of all the company's revenues generated from the sale of Rx Products. The term of the License Agreement continues until the expiration of the last of the Rx patents.